Piper Jaffray Companies reissued their hold rating on shares of Shire (NASDAQ:SHPG) in a research report sent to investors on Wednesday.
A number of other equities analysts have also recently commented on the company. Zacks Investment Research upgraded Shire from a sell rating to a hold rating in a report on Friday, October 27th. Royal Bank of Canada reaffirmed a buy rating on shares of Shire in a research report on Thursday, November 16th. Cantor Fitzgerald set a $222.00 price target on Shire and gave the company a buy rating in a research report on Thursday, November 16th. Cowen set a $225.00 price target on Shire and gave the company a buy rating in a research report on Sunday, October 29th. Finally, Stifel Nicolaus reaffirmed a buy rating and issued a $245.00 price target on shares of Shire in a research report on Sunday, October 8th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company’s stock. Shire presently has a consensus rating of Hold and an average target price of $212.18.
Shire (NASDAQ:SHPG) opened at $156.86 on Wednesday. Shire has a twelve month low of $137.17 and a twelve month high of $192.15. The company has a market capitalization of $47,303.71, a PE ratio of 29.37, a P/E/G ratio of 0.85 and a beta of 1.60. The company has a current ratio of 0.98, a quick ratio of 0.52 and a debt-to-equity ratio of 0.55.
Shire (NASDAQ:SHPG) last announced its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, beating analysts’ consensus estimates of $3.64 by $0.17. Shire had a return on equity of 14.41% and a net margin of 10.95%. The company had revenue of $3.70 billion during the quarter. During the same quarter last year, the business earned $3.17 earnings per share. The business’s revenue was up 7.1% compared to the same quarter last year. equities analysts anticipate that Shire will post 15 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the company. Seizert Capital Partners LLC raised its position in shares of Shire by 13.3% during the 3rd quarter. Seizert Capital Partners LLC now owns 10,786 shares of the biopharmaceutical company’s stock worth $1,652,000 after acquiring an additional 1,267 shares in the last quarter. Fisher Asset Management LLC increased its position in Shire by 2.9% during the third quarter. Fisher Asset Management LLC now owns 57,419 shares of the biopharmaceutical company’s stock worth $8,793,000 after buying an additional 1,619 shares during the period. Morningstar Investment Services LLC increased its position in Shire by 53.0% during the third quarter. Morningstar Investment Services LLC now owns 25,882 shares of the biopharmaceutical company’s stock worth $3,964,000 after buying an additional 8,969 shares during the period. Oak Ridge Investments LLC increased its position in Shire by 3.2% during the second quarter. Oak Ridge Investments LLC now owns 81,011 shares of the biopharmaceutical company’s stock worth $13,389,000 after buying an additional 2,528 shares during the period. Finally, Trillium Asset Management LLC increased its position in Shire by 2.3% during the third quarter. Trillium Asset Management LLC now owns 49,083 shares of the biopharmaceutical company’s stock worth $7,517,000 after buying an additional 1,082 shares during the period. 20.19% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Shire (SHPG) Given Hold Rating at Piper Jaffray Companies” was posted by Equities Focus and is the sole property of of Equities Focus. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.equitiesfocus.com/2018/01/07/shire-shpg-given-hold-rating-at-piper-jaffray-companies.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.